Cardiac Resynchronization Therapy—Emerging Therapeutic Approaches

被引:5
作者
Chatterjee N.A. [1 ,2 ]
Heist E.K. [1 ,2 ]
机构
[1] Cardiology Division and Cardiac Arrhythmia Service, Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street, Boston, 02114, MA
[2] Cardiology Division of the Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, 02114, MA
关键词
Cardiac resynchronization therapy; Heart failure; His bundle pacing; Leadless pacing;
D O I
10.1007/s11936-018-0614-2
中图分类号
学科分类号
摘要
Cardiac resynchronization therapy (CRT) is an important therapeutic tool in the management of patients with heart failure and electrical dyssynchrony. In appropriately selected patients, landmark randomized controlled trials have demonstrated morbidity and mortality benefit beyond standard goal-directed medical therapy. Current guidelines emphasize the greatest clinical efficacy of CRT in patients with symptomatic heart failure, left bundle branch block, and wide QRS duration (CloseSPigtSPi 150 ms). Other relevant considerations include the presence of atrial fibrillation, the presence of AV block, the etiology of cardiomyopathy, the presence of masked left-sided conduction delay, and the impact of comorbidities that might predict poor clinical response. At the time of CRT implantation, key considerations include targeting of the left ventricular (LV) lead to sites of greatest electrical and/or mechanical delay, the use of quadripolar versus bipolar LV pacing leads, evaluation of multiple pacing vectors to maximize electrical resynchronization, and in select instances pre-procedure imaging of the coronary venous anatomy to help guide decision-making at the time implant. Post-implant care includes the selective use of atrio-ventricular and inter-ventricular optimization algorithms, mitigation of right ventricular pacing, recognition, and treatment of suboptimal biventricular pacing, as well as management by a multi-disciplinary team of cardiovascular specialists. Emerging therapeutic strategies for patients eligible for CRT include the use of endocardial LV pacing, novel LV pacing options including multi-point pacing, His bundle pacing, and the integration of remote monitoring platforms that may identify patients at risk for clinical worsening. © 2018, Springer Science+Business Media, LLC, part of Springer Nature.
引用
收藏
相关论文
共 81 条
[1]  
Brignole M., Auricchio A., Baron-Esquivias G., Bordachar P., Boriani G., Breithardt O.A., Et al., 2013 ESC guidelines on cardiac pacing and cardiac resynchronization therapy: the task force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA), Europace: Eur Pacing, Arrhythmias, Card Electrophysiol: J Work Groups Card Pacing Arrhythmias Card Cell Electrophysiol Eur Soc Cardiol, 15,
[2]  
Epstein A.E., DiMarco J.P., Ellenbogen K.A., Estes N.A., Freedman R.A., Gettes L.S., Et al., 2012 ACCF/AHA/HRS focused update incorporated into the ACCF/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society, J Am Coll Cardiol, 61, 3, pp. e6-e75, (2013)
[3]  
Abraham W.T., Fisher W.G., Smith A.L., Delurgio D.B., Leon A.R., Loh E., Kocovic D.Z., Packer M., Clavell A.L., Hayes D.L., Ellestad M., Trupp R.J., Underwood J., Pickering F., Truex C., McAtee P., Messenger J., Cardiac resynchronization in chronic heart failure, Multicenter InSync Randomized Clinical Evaluation,N Engl J Med, 346, 24, pp. 1845-1853, (2002)
[4]  
Bristow M.R., Saxon L.A., Boehmer J., Krueger S., Kass D.A., De Marco T., Carson P., DiCarlo L., DeMets D., White B.G., DeVries D.W., Feldman A.M., Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure, N Engl J Med, 350, 21, pp. 2140-2150, (2004)
[5]  
Cleland J.G., Daubert J.C., Erdmann E., Freemantle N., Gras D., Kappenberger L., Tavazzi L., The effect of cardiac resynchronization on morbidity and mortality in heart failure, N Engl J Med, 352, 15, pp. 1539-1549, (2005)
[6]  
Moss A.J., Hall W.J., Cannom D.S., Klein H., Brown M.W., Daubert J.P., Estes N.A., Foster E., Greenberg H., Higgins S.L., Pfeffer M.A., Solomon S.D., Wilber D., Zareba W., Cardiac-resynchronization therapy for the prevention of heart-failure events, N Engl J Med, 361, 14, pp. 1329-1338, (2009)
[7]  
Tang A.S., Wells G.A., Talajic M., Arnold M.O., Sheldon R., Connolly S., Hohnloser S.H., Nichol G., Birnie D.H., Sapp J.L., Yee R., Healey J.S., Rouleau J.L., Cardiac-resynchronization therapy for mild-to-moderate heart failure, N Engl J Med, 363, 25, pp. 2385-2395, (2010)
[8]  
Mullens W., Grimm R.A., Verga T., Dresing T., Starling R.C., Wilkoff B.L., Tang W.H.W., Insights from a cardiac resynchronization optimization clinic as part of a heart failure disease management program, J Am Coll Cardiol, 53, 9, pp. 765-773, (2009)
[9]  
Cleland J.G., Freemantle N., Daubert J.C., Toff W.D., Leisch F., Tavazzi L., Long-term effect of cardiac resynchronisation in patients reporting mild symptoms of heart failure: a report from the CARE-HF study, Heart, 94, 3, pp. 278-283, (2008)
[10]  
Linde C., Abraham W.T., Gold M.R., St John Sutton M., Ghio S., Daubert C., Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms, J Am Coll Cardiol, 52, 23, pp. 1834-1843, (2008)